Pramipexole in Treatment Resistant Depression: A Case Review  

作　　者：Nada Abdallah Jeffrey Kahn Nada Abdallah;Jeffrey Kahn(Weill Cornell Medicine, New York, NY, USA;Department of Psychiatry, Weill Cornell Medicine, New York, NY, USA)

机构地区：[1]Weill Cornell Medicine, New York, NY, USA [2]Department of Psychiatry, Weill Cornell Medicine, New York, NY, USA

出　　处：《Pharmacology & Pharmacy》2023年第7期223-227,共5页药理与制药（英文）

摘　　要：Pramipexole is a dopamine agonist used in the treatment of Parkinson’s disease and Restless legs syndrome. Although off-label, the use of Pramipexole as an adjunct therapy in treatment resistant depression has recently been documented in the literature with promising results. We present a 75-year-old male with MDD who has failed trials of SSRIs, SNRIs, TCAs, SGA, TMS, Ketamine, and ECT who was initiated on Pramipexole. We discuss, based on existing literature, the probability of a favorable long-term response to Pramipexole and the potential side effects for our patient. We also highlight the need for future studies designed to test the efficacy of Pramipexole in geriatric patients with TRD.Pramipexole is a dopamine agonist used in the treatment of Parkinson’s disease and Restless legs syndrome. Although off-label, the use of Pramipexole as an adjunct therapy in treatment resistant depression has recently been documented in the literature with promising results. We present a 75-year-old male with MDD who has failed trials of SSRIs, SNRIs, TCAs, SGA, TMS, Ketamine, and ECT who was initiated on Pramipexole. We discuss, based on existing literature, the probability of a favorable long-term response to Pramipexole and the potential side effects for our patient. We also highlight the need for future studies designed to test the efficacy of Pramipexole in geriatric patients with TRD.

关 键 词：PRAMIPEXOLE Treatment Resistant Depression Augmentation Dopamine Agonism Geriatric Psychiatry 

分 类 号：R74[医药卫生—神经病学与精神病学]